What to Expect
(TRF) filled out and
sent to OncoHost
patient or clinic and
blood draw is
blood draw and
overnights it to the
analyzed at the
PROphet® is a first-of-its-kind platform that employs high-throughput proteomic pattern analysis technology to assess patient response to treatment, enabling oncologists to provide truly personalized care.
Analyzing just one pre-treatment blood sample, PROphet® scans proteins in your blood to identify patterns that decode the cancer resistance mechanisms in your body. These patterns are predictive of your likeliness to obtain clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment.
Utilizing bioinformatics and machine learning technology, PROphet® produces a personalized report answering an important clinical question:
What is the optimal first line of therapy for you?
How it works
blood test collected
at your own home or
with analysis of clinical
benefit and actionable insights
is sent to physician
PROphet® employs SomaScan® technology that scans approximately 7,000 proteins in your blood plasma, identifying proteomic patterns unique to you that serve as indicators of the cancer resistance mechanisms predictive of your treatment response. The proteins that are scanned include cytokines, chemokines, growth factors and enzymes associated with therapy resistance and tumor spread.
The result of this proteomic analysis provides your physician with precise, personalized clinical insights, allowing them to administer a treatment plan tailored to you.
Next-generation sequencing (NGS) is performed to obtain important information regarding the genomic and genetic make-up of your tumor. Some genetic alterations are known as “driver mutations” or “biomarkers,” which provide important information that will help guide your overall treatment plan.
Proteomic analysis used alongside NGS testing can provide your doctor with valuable insights into your tumor growth, the characteristics of your tumor, and what may impact your response to therapy.
What if my report shows that I have a NEGATIVE PROphet® result? Does this mean I won’t respond to any treatment?
The alternative treatment options suggested in the report are all either FDA-approved treatments or those currently in late-stage clinical trial development.
What if my report shows that I have a POSITIVE PROphet® result? Does this mean I will respond to treatment?
Biomarkers: Information that reduces the guesswork
The concept of precision oncology – treatment strategies that take individual
variability into account – hinges on developing robust biomarkers that provide
prognostic or predictive information regarding potential response to therapies.
Not all biomarkers are created equal
Most precision oncology tools focus on the contribution of intrinsic
changes that predict drug resistance, such as genetic mutations and
epigenetic alterations within tumor cells.
But a growing body of evidence demonstrates that cancer and its
potential therapy can induce a range of systemic biological processes
and molecular changes that enter an interplay between the tumor, the
patient, and the therapy.
This interaction can promote tumor regrowth and metastasis through
angiogenesis, immune modulation, and other resistance-associated
mechanisms, thereby partially or completely negating the intended
OncoHost is taking a different approach
to precision medicine
OncoHost for patient
Explanation of Benefits
from insurance company
(this is not a bill)
invoice to patient with
Financial assistance is available for qualifying patients who have out-of-pocket costs associated with OncoHost’s PROphet® test.*
Financial assistance is based on need and can be applied for at any time before during or after testing. Payment plans may also be available based on your financial situation.
For any additional information or questions about our billing process, insurance, or Medicare coverage,
please reach out to our client services team via email at email@example.com or by phone at 1-855-950-2112.
* OncoHost’s Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.